Empagliflozin for heart failure & diabetes: quality of life study
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This trial tests whether a diabetes medicine called empagliflozin can improve the quality of life for people who have both chronic heart failure with a weak heart pump and type 2 diabetes. It compares the effects of adding empagliflozin to your current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 70 years old.
- You have heart failure that limits your daily activities (NYHA class II–IV).
- Your heart's pumping strength is less than 40% (low ejection fraction).
- You have type 2 diabetes and are taking medication for it.
- You are not pregnant, have no severe kidney disease, and haven't had a recent heart attack or sudden worsening of heart failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This study tests whether a medication called empagliflozin (a diabetes drug) can improve heart function in older adults with high blood pressure and obesity who are at risk for heart failure but do not have it yet. You would take the pill daily and have heart ultrasounds to check your heart's health.
This trial tests if empagliflozin, a diabetes medicine that also helps the heart, can improve symptoms in children with heart failure. It may help kids with severe symptoms or high levels of a heart stress marker called BNP.
This trial tests if a diabetes medicine called empagliflozin can help people with Fontan circulatory failure feel better and do more of their daily activities.
This study tests whether continuing empagliflozin (a heart failure medicine) during a hospital stay for heart failure is beneficial compared to stopping it. Participation may help improve recovery and reduce complications.
Hear when a new Chronic Heart Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.